A genetic test that measures 22 genomic biomarkers associated with metastatic prostate cancer (PCa) may be able to outperform other risk assessment tools for predicting metastatic PCa in patients following radical prostatectomy.

Continue Reading

John Schieszer reports in today’s Medical Minute that this test correctly reclassified 60% of high-risk patients as having low-risk disease and better identified those patients who were more likely to develop metastatic PCa.